87 related articles for article (PubMed ID: 37670888)
1. Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.
Wang BD; Ceniccola K; Hwang S; Andrawis R; Horvath A; Freedman JA; Olender J; Knapp S; Ching T; Garmire L; Patel V; Garcia-Blanco MA; Patierno SR; Lee NH
Nat Commun; 2017 Jun; 8():15921. PubMed ID: 28665395
[TBL] [Abstract][Full Text] [Related]
2. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
[TBL] [Abstract][Full Text] [Related]
3. Aberrant RNA Splicing in Cancer and Drug Resistance.
Wang BD; Lee NH
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463359
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the Concealed Transcriptomic Landscape of PTEN in Human Malignancies.
Boti MA; Adamopoulos PG; Vassilacopoulou D; Scorilas A
Curr Genomics; 2023 Dec; 24(4):250-262. PubMed ID: 38169628
[TBL] [Abstract][Full Text] [Related]
5. JAK3/STAT5 signaling-triggered upregulation of PIK3CD contributes to gastric carcinoma development.
Hu Q; Dou N; Wu Q; Gao Y; Li Y; Chen J
J Cell Commun Signal; 2024 Mar; 18(1):e12017. PubMed ID: 38545256
[TBL] [Abstract][Full Text] [Related]
6. Activated PI3Kδ Specifically Perturbs Mouse Regulatory T Cell Homeostasis and Function Leading to Immune Dysregulation.
Singh AK; Al Qureshah F; Drow T; Hou B; Rawlings DJ
J Immunol; 2024 Jun; ():. PubMed ID: 38829130
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic role of a developmentally regulated
Pattwell SS; Arora S; Nuechterlein N; Zager M; Loeb KR; Cimino PJ; Holland NC; Reche-Ley N; Bolouri H; Almiron Bonnin DA; Szulzewsky F; Phadnis VV; Ozawa T; Wagner MJ; Haffner MC; Cao J; Shendure J; Holland EC
Sci Adv; 2022 Oct; 8(40):eabo6789. PubMed ID: 36206341
[TBL] [Abstract][Full Text] [Related]
8. LINC00839 in Human Disorders: Insights into its Regulatory Roles and Clinical Impact, with a Special Focus on Cancer.
Hu Y; Hu Y; Lu X; Luo H; Chen Z
J Cancer; 2024; 15(8):2179-2192. PubMed ID: 38495499
[TBL] [Abstract][Full Text] [Related]
9. Correction: PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
Miller KA; Degan S; Wang Y; Cohen J; Ku SY; Goodrich DW; Gelman IH
Oncogene; 2024 Jan; 43(1):76. PubMed ID: 38097735
[No Abstract] [Full Text] [Related]
10. 30 years of PI3K: an interview with Bart Vanhaesebroeck.
Vanhaesebroeck B
Future Oncol; 2024 May; ():1-4. PubMed ID: 38713423
[No Abstract] [Full Text] [Related]
11. Clinical and genetic analysis of immunodeficiency-related diseases associated with
Zhang Q; Ma H; Ma J; Wang D; Zhao Y; Wang T; Li Z; Wu R; Zhang R
Pediatr Investig; 2018 Dec; 2(4):257-262. PubMed ID: 32851276
[No Abstract] [Full Text] [Related]
12. Ang-1 and VEGF: central regulators of angiogenesis.
Zhao Y; Yu B; Wang Y; Tan S; Xu Q; Wang Z; Zhou K; Liu H; Ren Z; Jiang Z
Mol Cell Biochem; 2024 Apr; ():. PubMed ID: 38652215
[TBL] [Abstract][Full Text] [Related]
13. Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.
Waseem M; Wang BD
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256166
[TBL] [Abstract][Full Text] [Related]
14. Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers.
Ha S; Gujrati H; Wang BD
Front Endocrinol (Lausanne); 2023; 14():1190479. PubMed ID: 37670888
[TBL] [Abstract][Full Text] [Related]
15. Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant
Ha S; Wang BD
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831678
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of miR-99b-5p and Upregulation of Nuclear mTOR Cooperatively Promotes the Tumor Aggressiveness and Drug Resistance in African American Prostate Cancer.
Gujrati H; Ha S; Waseem M; Wang BD
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077039
[TBL] [Abstract][Full Text] [Related]
17. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
[TBL] [Abstract][Full Text] [Related]
18. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
Nozhat Z; Hedayati M
Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
